Alcohol use is not a significant contributor to myelodysplastic syndromes
Abstract
PURPOSE:
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-drome
Myelodysplastic Syndromes (MDS)
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities
BACKGROUND:
Abnormalities of chromosome 3 in myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PL
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM)
The 2016 revision of the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues is characterized by a closer integration of morphology morphology: The study of t
Luspatercept-aamt
REBLOZYL® (luspatercept-aamt) is the first erythroid maturation agent (EMA) approved by the US Food and Drug Administration and European Union for the treatment of anemia anemia: (uh-NEE-mee-uh) A condition in which
Elena Solomou, MD, PhD
Institution
Patras University Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Barry Skikne, MD
Institution
Westwood Medical Pavilion and the Richard and Annette Bloch Cancer Care Pavilion
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Barry Skikne is certified by the American Board of Internal Medicine with a subcertification in hematology. He completed a fellowship at the University of Kansas Medical Center. He earned his medical degree from the University of Witwatersrand and completed his residency at Johannesburg Hospital.
Roberto Ovilla Martinez, MD
Institution
Hospital Angeles Lomas
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Luca Malcovati, MD
Institution
IRCCS S. Matteo Hospital Foundation & University of Pavia
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Malcovati is an Associate Professor of Hematology at the University of Pavia Medical School and with special interest and expertise in myeloid neoplasms, in particular, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Dr. Malcovati's research group has made a significant contribution to understanding the molecular basis of myeloid neoplasms and to the integration of somatic mutations in the clinical management of patients.